Dyne Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the fiscal quarter ended September 30, 2026.
Key Highlights
- Shares outstanding: As of October 30, 2026, the registrant had 187,386,963 shares of common stock, $0.0001 par value per share, outstanding.
- Filer classification: Dyne Therapeutics reported as a large accelerated filer for the period, not a smaller reporting company or emerging growth company.
- Loan agreement disclosed: The company disclosed an existing loan agreement with Hercules Capital, Inc. and cited obligations to comply with its restrictive covenants and satisfy interest and principal payments.
- Commercialization timeline: According to the filing, the company does not expect to have a product candidate ready for commercialization "at least until 2027, if ever."
- Exchange listing: Common stock is listed on the Nasdaq Global Select Market under the trading symbol DYN, with a par value of $0.0001 per share.
- FORCE platform: The filing identifies the company's proprietary FORCE platform as a key element of its research and development strategy across multiple product candidates.
Dyne Therapeutics Discloses Financial Position and Pipeline Status for September 30, 2026 Quarter
Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, submitted its Form 10-Q for the quarterly period ended September 30, 2026. The filing was made under Commission File Number 001-39509 and covers the registrant's financial condition, results of operations, and risk factors as of that date. The company confirmed it had 187,386,963 shares of common stock outstanding as of October 30, 2026.
According to the filing, Dyne Therapeutics holds product candidates at "varying stages of preclinical and clinical development" and has not completed clinical development of any product candidate. The company stated it does not expect a product candidate to be ready for commercialization "at least until 2027, if ever." The filing also disclosed the existence of the Loan Agreement with Hercules Capital, Inc., noting the company's obligations to comply with its restrictive covenants and to satisfy interest and principal payments under that agreement.
The filing notes that the company will need "substantial additional funding" and warns that if it is unable to raise capital when needed, it "could be forced to delay, reduce or eliminate" its product development programs or commercialization efforts. These statements are the company's own forward-looking disclosures and are subject to the cautionary language included in the filing. The registrant confirmed it is not a shell company and checked "Yes" to having filed all required reports during the preceding 12 months.
What Was Disclosed
Dyne Therapeutics filed its quarterly report for the period ended September 30, 2026, disclosing 187,386,963 shares outstanding, its large accelerated filer status, an existing loan agreement with Hercules Capital, and a stated commercialization timeline of no earlier than 2027.




Please wait processing your request...